TBPH Q3 2021 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M-27.7% YoY

Gross Profit

-$31M-231.5% margin

Operating Income

-$54M-406.4% margin

Net Income

-$35M-267.6% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$46M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$403M

Total Liabilities

$727M

Stockholders' Equity

-$324M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$18M	-27.7%
Gross Profit	-$31M	$18M	-267.3%
Operating Income	-$54M	-$77M	+30.0%
Net Income	-$35M	-$74M	+52.1%

Revenue Segments

Viatris collaboration agreement

$10M79%

Collaborative revenue

$3M21%